Introduction
Compounds with the biological activity of vitamin A have profound eects on cell proliferation and dierentiation, both in vitro and in vivo (Means and Gudas, 1995) . Of these, retinoic acid (RA) appears to have the widest range of activity. The action of retinoic acid is mediated by two families of ligand activated nuclear receptors. One, the retinoic acid receptors (RARa, RARb and RARg), bind both the all-trans and 9-cis isomers of RA as well as other retinol metabolites, whereas the second, the retinoid X receptors (RXRs) bind only 9-cis retinoic acid with high anity (Chambon, 1996; Mangelsdorf et al., 1994) . The RARs and RXRs are nuclear phosphoproteins that have ligand-dependent transcriptional regulatory activity. RARs bind to speci®c DNA sequences as heterodimer partners of the RXRs. Ligand binding induces conformational changes in the RARs that result in decreased association with co-repressors (Chen and Evans, 1995; Kurokawa et al., 1995) and allow association with co-activators such as CBP and p300 (Kamei et al., 1996) .
Inhibition of tumor cell proliferation by retinoids correlates with the ability of these compounds to interfere with the activity of AP1 Nagpal et al., 1995; Nicholson et al., 1990; Pfahl, 1993; Schule et al., 1991; Soprano et al., 1996; Talmage and Lackey, 1992) . The anti-AP1 activity of retinoids has been attributed to three distinct properties of the RARs. First, in transient co-transfection experiments, RARs physically interact with c-Jun, and prevent AP1 from transactivating target genes (Nicholson et al., 1990; Pfahl, 1993; Schule et al., 1991) . Second, both RAR and AP1 transactivation of target genes is mediated by common co-activators, p300 or CBP, that are thought to be expressed at limiting levels relative to AP1 or RAR (Kamei et al., 1996) . Following ligand binding, the RARs successfully compete with AP1 for these limiting co-activators. Neither of these mechanisms invoke a tumor suppressive role for products of genes that are direct targets for RAR:RXR transcriptional induction. A third alternative, involves a RA-dependent inhibition of the expression of the AP1 components, c-Fos, c-Jun or both (Busam et al., 1992; Caelles et al., 1997; Fisher et al., 1998; Khuri et al., 1996; Talmage and Lackey, 1992; Talmage and Listerud, 1994) . By utilizing polyoma virus as a potent, well characterized oncogenic agent, we demonstrated that RA prevents transcriptional transactivation of the c-fos protooncogene and the subsequent increases in AP1 activity. Because of the failure to induce c-Fos expression, the viral middle T oncoprotein was unable to transform RA-treated cells (Talmage and Lackey, 1992; Talmage and Listerud, 1994) . The anti-AP1 action of RA in this example further diered from the previous examples because it required expression of an RA-induced gene or genes.
Polyoma virus middle T transforms cells in vitro and in vivo by binding to and constitutively activating src family tyrosine kinases (Courtneidge and Smith, 1983; Freund et al., 1992b) . A critical substrate for activated p60 c-src is middle T itself. In kinase active mT:p60 c-src complexes, p60 c-src phosphorylates middle T on three tyrosine residues, tyrosines 250, 315 and 322 (Dilworth et al., 1994; Harvey et al., 1984; Schahausen and Benjamin, 1981) . Phosphorylation of these tyrosines results in the activation of three distinct, although interactive, signaling cascades. Genetic and biochemical analyses have established that phosphotyrosine-250 is bound by the adapter protein, Shc (Dilworth et al., 1994) , phosphotyrosine-315 is bound by phosphatidylinositol 3-kinase (PtdIns 3-kinase) (Talmage et al., 1989) and phosphotyrosine-322 is bound by phospho-lipase Cg (Su et al., 1995) . By recruiting these proteins to complexes active in signaling, mT:pp60 c-src is functionally equivalent to ligand activated receptor tyrosine kinases such as the platelet derived growth factor and epidermal growth factor receptors. Point mutations that replace either tyr-250 or tyr-315 with other amino acids, reduce transformation by middle T by greater than 90% in cell culture assays and reduce tumor induction in polyoma virus infected mice (Carmichael et al., 1984; Freund et al., 1992a; Harvey et al., 1984; Talmage et al., 1989; Yi et al., 1997) . Substitution of tyr-322 with phenylalanine has limited eect on in vitro transformation and no eect on tumor induction in vivo (Su et al., 1995; Freund, unpublished) .
Signals originating with tyrosine kinase active mT:pp60 c-src complexes ultimately reach the nucleus and alter expression of target genes (Matrisian et al., 1985; Wasylyk et al., 1988; Zullo et al., 1987) . Previously we demonstrated that c-fos expression is required for polyoma virus to transform cells and that resistance of RA-treated cells to polyoma virus transformation results from an RA block of the transcription of the c-fos gene (Talmage and Lackey, 1992; Talmage and Listerud, 1994) . The mechanism(s) by which polyoma virus activates the c-fos promoter has not been fully characterized. Polyoma virus activation of c-fos expression requires middle T and/ or small T functions (Rameh and Armelin, 1991; Zullo et al., 1987) , and in part requires PtdIns 3-kinase and the cis-acting serum response element, SRE (Glenn and Eckhart, 1993; Urich et al., 1995) .
We postulated that transcriptional repression of cfos by RA resulted from disruption of a subset of the signaling cascades activated by tyrosine kinases (both mT:pp60 c-src and receptor tyrosine kinases) (Talmage and Lackey, 1992; Talmage and Listerud, 1994) . In order to test this prediction, we have carried out a detailed characterization of the signaling pathways and the relevant cis-acting elements in the c-fos promoter that are utilized by middle T. Our results demonstrate that middle T transactivation of c-fos requires PtdIns 3-kinase signaling to both the serum and cAMPresponse elements, and that PtdIns 3-kinase signals are transmitted by the small GTP-binding protein Rac and the Jun N-terminal kinases. We also demonstrate that retinoic acid inhibits middle T (and serum growth factor) activation of JNKs, thereby preventing c-fos transactivation and transformation.
Results
Middle T interaction with PtdIns 3-kinase is necessary, but not sucient, for transactivation of the c-fos promoter Expression of middle T results in transcriptional transactivation of the c-fos promoter, a response that is required for transformation and that is inhibited by retinoic acid (Talmage and Listerud, 1994) . In order to determine which middle T functions activate the c-fos promoter, F111 and F111 cells expressing wild type (which binds pp60 c-src , PtdIns 3-kinase and Shc), PyY250S (which binds pp60 c-src and PtdIns 3-kinase but not Shc), PyY315F (which binds pp60 c-src and Shc but not PtdIns 3-kinase) or Py1387T (which fails to activate pp60 c-src and therefore does not bind to PtdIns 3-kinase or Shc) middle Ts were transiently transfected with a c-fos promoter-CAT reporter plasmid (pF359CAT). Cells were serum starved, and total CAT activity was determined in cell extracts 20 ± 24 h later. Cells expressing wild type middle T, but not PyY315F or Py1387T mutant middle T, had elevated CAT activity (3.5-fold), compared to serum starved control cells (F111 cells not expressing T antigens) (Figure 1a ). CAT activity in PyY250S middle T expressing cells also was not signi®cantly elevated relative to control cells. The mouse c-jun (Figure 1b) and an arti®cial AP1 (containing ®ve repeats of the collagenase promoter AP1 site; Figure 1c ) promoters were also activated by wild type middle T (*10-fold) but not by either PyY315S or Py1387T middle T. In the case of PyY250S, c-jun promoter activity was elevated relative to control cells or cells expressing the other middle T mutants, but only to *30% of wild type levels. The inability of either PyY315F or Py1387T middle T to transactivate the c-fos promoter in these experiments indicates that the transactivation function of middle T was pp60 c-src -and PtdIns 3-kinasedependent. However, since PyY250S middle T was at best partially active in these assays, pp60
c-src and PtdIns 3-kinase interactions with middle T were not sucient for transactivation of the promoters tested. This result indicates that two distinct middle T activated pathways, one involving PtdIns 3-kinase signaling, the second presumably involving Shc/Ras/MAPK signaling, act together to transactivate these promoters.
Middle T activation of the c-fos promoter requires Rac and JNK
Members of the Rho family of small GTP binding proteins, in particular Rac and Cdc42Hs, mediate PtdIns 3-kinase activation of JNK (Coso et al., 1995; Crespo et al., 1996; Minden et al., 1995) . Both Rac and Cdc42Hs activity are required for middle T transformation (Urich et al., 1997;  Table 1 ), and active forms of both can transactivate the c-fos promoter (Alberto et al., 1998; Hill et al., 1995; . In order to characterize the pathway from mT:pp60 c-src :PtdIns 3-kinase to the c- After 24 h in low serum (0.2% calf serum) whole cell extracts were assayed for CAT activity. Results from 3 ± 6 experiments on at least two clones of each cell line were averaged for this ®gure. * indicates that the value diers signi®cantly from F111 control levels (Student's ttest, P50.01)
fos promoter, F111-PymT cells were co-transfected with the pF359CAT reporter plasmid and expression plasmids encoding dominant negative mutant forms of the small GTPases p21
H-ras (RasN17), Cdc42Hs (Cdc42N17) and Rac1 (Rac1N17), each encoding Asn at codon 17 (Chou and Blenis, 1996) , as well as a catalytically inactive mutant of JNK1 (JNK DN ; Minden et al., 1995) . Expression of Rac1N17 or JNK DN reduced c-fos promoter activity in F111-PymT cells by 91% or 62% respectively (Figure 2) . Consistent with the presence of a middle T-activated signaling pathway that sequentially activates Rac and JNK, dominant negative forms of both of these proteins inhibited middle T activated JNK in co-transfection experiments (data not shown). Expression of a dominant negative form of Cdc42Hs (Cdc42N17), which is closely related to Rac, did not signi®cantly aect c-fos promoter activity. Transfection with the RasN17 mutant variably reduced expression from the pF359CAT reporter plasmid. Cotransfection of the RasN17 and pF359CAT plasmids resulted in CAT activities ranging from 50 ± 90% (average of 75+27%) of CAT levels seen in cells transfected with just pF359CAT. This variation was due to inter-experimental and not intra-experimental dierences in RasN17 action, perhaps indicating that an as yet uncharacterized variable in¯uences the relative role of Ras in middle T signaling to the c-fos promoter.
The importance of Ha-Ras, Cdc42Hs, Rac, and JNK in mediating middle T induced transformation was determined. F111-RARa cells were cotransfected with a plasmid encoding wild type middle T (pPyBR), along with each of the dominant negative mutants described above. The extent by which these dominant negative mutants blocked middle T-induced transformation was determined by counting foci 14 days after co-transfection. Expression of Rac1N17, RasN17, Cdc42N17 or JNK DN blocked the middle Tinduced transformation by 85%, 75%, 43% or 47% respectively (Table 1) . Compared to RasN17, Cdc42N17 and JNK DN , co-transfection of the dominant negative form of Rac1 was most eective in inhibiting focus formation by middle T. This experiment con®rmed previous reports demonstrating that middle T transformation requires Rac, H-Ras and Cdc42Hs activity (Raptis et al., 1991; Urich et al., 1997) , as well as establishing a requirement for JNK activity. These results do not determine whether the requirement for these signaling proteins is speci®c for middle T induced focus formation, or represent a more general requirement for their activity in maintaining cellular proliferation or viability. Indeed, we have been unable to establish F111 or F111-PymT cell lines that stably express Rac1N17 or JNK DN .
The eects of Rac1N17 in the above experiments were quantitatively similar to the eects of retinoic acid previously reported (Talmage and Lackey, 1992; Talmage and Listerud, 1994) . To determine if retinoic acid was acting by inhibiting signaling between the middle T:pp60 c-src :PtdIns 3-kinase ternary complex, and the c-fos promoter, we established F111 derived cell lines expressing both RARa and middle T (either wild type or the Y315F mutant). These cells are therefore, retinoic acid responsive. Retinoic acid activation of RARa reversed the transformed phenotype of middle T expressing cells. When RARa and the wild type polyoma early region were co-expressed, the cell morphology was typical of polyoma virus transformed cells. Treatment of F111-RARa-PymT cells with retinoic acid (10 76 M) for 4 days altered the growth properties and morphology of these cells. RA treatment caused cells F111-RARa cells were transfected with 1 or 2 mg of the plasmid containing wild type mT DNA (pPyBR) and 5 mg of vectors expressing the indicated dominant negative mutants. After 14 days, cells were stained with 0.1% Giemsa and foci were quanti®ed. Assays with 200 foci represent estimates, since accurate counts were dicult when >150 foci are present on single dishes. The results from six seperate experiments are shown as foci per 60-mm dish. The percent of inhibition was determined by using the formula: 100-(foci obtaind in the presence of mT and dominant negative mutants/foci obtained in the presence of mT alone ).The average percent of inhibition by Rac1N17, RasN17, JNK DN or Cdc42N17 is shown in the last column. ND, not determined Figure 2 Mutant forms of Rac1 (by 91%) and JNK1 (by 62%), but not Ras or Cdc42Hs inhibit middle T transactivation of the cfos promoter. F111-PymT cells were co-transfected with the pF359CAT reporter plasmid and expression vectors encoding dominant interfering mutants of Ras (RasN17), Cdc42Hs (Cdc42N17), Rac1 (Rac1N17) or JNK1 (JNK DN ). After 20 ± 24 h in 0.2% calf serum, cells were lysed and CAT activity was measured. Data are expressed relative to values obtained in the absence of co-transfected mutants (=100%). *signi®cant at P50.01
to acquire a phenotype more closely resembling the parental cells and decreased total cell number ( Figure  3a ). During mid-log growth (typically between days 2 and 4 after plating) RA treated F111-RARa-PymT cells grew at the same rate as F111-RARa cells, and more slowly than F111-RARa-PymT cells without RA treatment (Figure 3b ). This is seen clearly when this data is re-plotted on a semi-log plot (Figure 3c ), where the mid-log growth rates, represented by the slopes of the curves, can be directly compared. During this period, F111-RARa cells underwent 1.5 population doublings, F111-RARa-PymT cells doubled three times and RA treated F111-RARa-PymT cells underwent two population doublings. Two additional observations resulted from these experiments. First, and not readily apparent from the graph shown, the RA eect was delayed. In repeated experiments, during the ®rst 48 h, RA-treated cells grew at a rate equivalent to untreated cells. A similar delay also occurred before visible morphological changes were observed. Second, although, the mid-log growth rate of F111-RARa-PymT cells was normalized by RA, saturation densities remained elevated (Day 5, Figure 3b ). These results indicate that retinoic acid reverses many, but not all middle T-induced changes in the regulation of F111-RARa cell proliferation.
To con®rm that the RA-dependent reversion of the middle T-induced transformed phenotype was associated with decreased c-fos promoter activity and resulted from a disruption in PtdIns 3-kinase signaling, we compared the activity of the c-fos promoter in F111-RARa-PymT and F111-RARa-PyY315F cells following treatment with either RA or PtdIns 3-kinase inhibitors. Inhibition of PtdIns 3-kinase activity with wortmannin reduced c-fos promoter activity by 460% (Figure 3d ; similar results were obtained with a second PtdIns 3-kinase inhibitor, LY294002 not shown). These results con®rmed the role of PtdIns 3-kinase as a mediator of middle T transactivation of the c-fos promoter. The CAT activity that remained in wortmannin treated cells was equivalent to the CAT activity seen in PyY315F expressing cells and wortmannin had no eect on CAT expression in PyY315F expressing cells. A 3 day pretreatment with RA also reduced CAT activity in wild type middle T expressing cells. CAT activity in RA-treated cells was equal to that in untreated PyY315F expressing cells and in wild type middle T expressing cells in which PtdIns 3-kinase activity had been inhibited with either wortmannin or LY294002. Neither RA nor wortmannin aected CAT activity in cells expressing the PyY315F middle T that does not bind to PtdIns 3-kinase. The essentially equivalent eects of wortmannin, the Y315F mutation and RA treatment strongly supports the conclusion that RA disrupts signaling between the middle T:pp60 c-src :PtdIns 3-kinase ternary complex, and the c-fos promoter. Retinoic acid inhibits JNK activity RA inhibits middle T transactivation of the c-fos promoter to the same extent as PtdIns 3-kinase inhibitors (Figure 3d ). Based on these observations we predicted that retinoic acid inhibits middle T transformation and c-fos transactivation by inhibiting a PtdIns 3-kinase initiated signaling pathway. PtdIns 3-kinase activates at least ®ve serine/threonine protein kinases: PKCz (Nakanishi et al., 1993) , Akt-1 (Franke et al., 1995; Mieli et al., 1998), p70 s6k (Cheatham et al., 1994; Dahl et al., 1996; Talmage et al., 1988) , the mitogen activated protein kinases (Erks or MAPKs; Hu et al., 1995; Urich et al., 1995) and the Jun Nterminal protein kinases (JNKs; Sinivas et al., 1994; Minden et al., 1995) . Both MAPK and JNK phosphorylate factors that activate c-fos transcription (Gupta et al., 1995 (Gupta et al., , 1996 Janknecht and Nordheim, 1996; Price et al., 1996; . In addition, Rac and Cdc42Hs activate c-fos transcription by modifying histone acetylation through poorly de®ned intermediates (Alberto et al., 1998) . The ability of wild type middle T to constitutively activate MAPK and JNK, and the eect of retinoic acid treatment on the activity of these kinases, was assessed by measuring speci®c kinase activity in immunecomplexes prepared from F111-RARa and F111-RARa-PymT cells. Broad speci®city antibodies to MAPK and JNK were used to ensure measuring the activity of all isoforms of these kinases. Serum starved F111-RARa-PymT cells had elevated MAPK (4 ± 5-fold) and JNK (8 ± 10-fold) activity relative to F111-RARa cells (Figure 4) . Treatment of F111-RARa-PymT cells with RA for 3 days signi®cantly decreased JNK activity (by *50%) but had no eect on MAPK. Pre-treatment of serum starved F111-RARa cells with RA for 18 h also prevented serum induction of JNK activity, again with no eect on serum induction of MAPK.
Immunoblotting analysis of F111-RARa and F111-RARa-PymT cells con®rmed that the middle T or retinoic acid induced changes in MAPK and JNK activity described above re¯ected changes in the activity of pre-existing enzyme rather than induction (or repression) of new enzyme synthesis ( Figure 5 ). Additionally RA treatment did not decrease Rac or Cdc42Hs expression, indeed if anything, both Rac and Cdc42Hs protein levels were elevated after RA treatment.
If Rac and JNK were speci®cally required for middle T induced transformation (and c-fos expression) and if RA inhibited transformation by preventing middle T activation of this pathway, activating this pathway in the presence of RA should restore focus formation by middle T in RA-treated cells. We tested this prediction using a constitutively active mutant of Rac1, Rac1V12. F111-RARa cells were transfected with either pPyBR (encoding wild type middle T), Rac1V12, pPyBR+Rac1N17 or pPyBR+Rac1V12. pPyBR and pPyBR+Rac1V12 cultures also were treated with RA. After 14 days, dense foci were quanti®ed ( Figure 6 Table 1 ). Both RA treatment and the dominant negative Rac1 mutant inhibited PyBR induced focus formation (by 80 ± 85%). Alone, Rac1V12 did not induce focus formation of F111 cells, but cotransfection of Rac1V12 with PyBR overcame the inhibitory eect of RA treatment. This result con®rms the speci®c role of Rac in middle T-induced transformation by demonstrating that reactivation of this pathway overcomes the anti-oncogenic eects of RA. This result also indicates that RA blocks middle T signaling upstream of Rac.
Middle T transactivation of c-fos requires cis-acting sequences that are potential binding sites for JNK substrates
Three cis-acting elements are required for mitogenic stimulation of c-fos transcription. The three elements required are the sis-inducible element (SIE, from nucleotide 7324 to 7345), the serum response element (SRE from nucleotide 7294 to 7315, including both the dyad symmetry element bound by the serum response factor, SRF, and the adjacent ternary complex factor binding site) and the cyclic AMP-response element (CRE from nucleotide 758 to 764). To determine which of these elements mediate middle T transactivation of the c-fos promoter, F111-PymT cells were transfected with reporter constructs in which these elements were deleted or altered by sitedirected mutagenesis. Deletion of the SIE had no eect on c-fos promoter activity in these cells (Figure 7 ; 7359/+12 compared to 7325/+12). Deletion of the SRE and sequences up to the CRE reduced promoter activity by *80% (compare the results of 7325/+12 with 775/+12). The remaining activity was lost when the promoter proximal sequences that included the CRE (between 775 and 732) were deleted. These results are consistent with an important role for both the SRE and the CRE in mediating middle Tdependent activation of the c-fos promoter.
To con®rm that both the SRE and the CRE were targets for middle T transactivation, and to determine if activation of the SRE required ternary complex formation, point mutations in each element were introduced into pF359CAT. Mutation of the CRE (from AGTGACGTCAGGA to ACTCAGCTCAGGA; CRE7) decreased promoter activity to *60% of the level of the intact pF359CAT, thus con®rming a signi®cant role for the CRE as a middle T target. Because the ternary complex factor proteins, Elk-1 and Sap-1, are substrates for MAPK, JNK and p38, and mediate receptor tyrosine kinase activation of c-fos expression (Gupta et al., 1996; Nordheim, 1996, Janknecht et al., 1995; , we mutated the Tcf binding site (Tcf7) adjacent to the dyad symmetry component of the SRE from AGGATG-TCCATATTAGGA to ACCATGTCCA-TATTAGGA. When transfected into F111-PymT cells this mutation was found to have eliminated middle T transactivation of the c-fos promoter. This mutation also lowered basal activity of the c-fos promoter in F111 cells, but retained serum responsiveness (not shown). The more dramatic eect of base substitutions at the Tcf binding site compared to deleting these sequences entirely, could indicate either a complex interplay between the SRE and CRE in middle T expressing Figure 6 Constitutively active Rac1 restores middle T-induced transformation in the presence of retinoic acid. F111-RARa cells were transfected with pPyBR alone (mT), or with a plasmid expressing Rac1V12. After 14 days in the presence (RA+) or absence of retinoic acid (RA7) dense foci were quanti®ed. The number of foci/plate in each case was normalized to the number induced by mT alone, in the absence of RA (=100%). The data represent the means from four independent experiments. Rac1V12 alone induced no detectable dense foci Figure 7 Middle T transactivates the c-fos promoter via two cisacting elements. F111-PymT cells were transfected with the reporter constructs illustrated on the left and serum starved. The numbers indicate the c-fos promoter sequences present in each construct. Twenty to 24 h later extracts were assayed for CAT activity. CAT activity is shown on the right (solid bars) and is expressed relative to pF359CAT (=100%). The positions of the serum response element (SRE), the cyclic AMP response element (CRE) and the TATA box are indicated. The black bars through the SRE or CRE indicate the position of the point mutations generated (see text for details). Deletion (775/+12) or point mutation of the SRE and the adjacent ternary complex factor binding site, (Tcf7), reduced promoter activity by 80 and 95% respectively. The CRE accounted for 20 ± 40% of middle T transactivation cells, or the creation of a novel, negative element by the mutation. The existence of interplay between the SRE and CRE was supported by measuring the activity of the promoter construct pSRE/775/+12CAT (in which the SRE was ampli®ed by PCR and ligated directly to the 775/+12CAT construct). Juxtaposition of these two elements reduced both basal and middle T activation of this reporter to the same levels as the Tcf point mutation in pF359CAT without aecting serum responsiveness (data not shown). Therefore middle T signaling to the c-fos promoter requires at least two ciselements that, within the native promoter, act in concert to regulate transcription.
Although these results implicate Elk-1 as the most likely JNK substrate for mediating middle T activation of the c-fos promoter, two additional experiments have not supported this conclusion. First, we have not detected elevated Elk-1 phosphorylation on serine-383, in F111-PymT cells compared to F111 cells. Second, expression of a dominant negative Elk-1 mutant did not inhibit middle T-induced focus formation as predicted; instead co-transfection of F111 cells with this mutant increased middle T-induced focus formation (by *50%, Chen and Talmage, preliminary observation). These results leave the targets that mediate Rac/JNK activation of the c-fos promoter in middle T expressing cells unidenti®ed.
Discussion
In this study we demonstrate that middle T transactivation of the c-fos promoter requires formation of the mT:pp60 c-src :PtdIns 3-kinase ternary complex, and that in this context PtdIns 3-kinase acts through JNK and Rac. Further, we have identi®ed inhibition of JNK as a mechanism for both the antioncogenic and anti-AP1 activity of retinoic acid.
The polyoma virus middle T oncoprotein transforms cells by activating the non-receptor tyrosine kinase, p60 c-src . Activated p60 c-src phosphorylates middle T on at least three tyrosines that serve as nucleation sites for signaling complexes. As a result middle T activates three distinct signaling pathways. Two of these pathways, known to be important for transformation of cells, activate parallel MAPK-like signaling modules (reviewed by Minden and Karin, 1997) . One (involving Ras/Raf/MEK/MAPK), is activated by mitogens, contains at least two proto-oncogene products, Ras and Raf, and is important for middle T oncogenesis (Raptis et al., 1991; Smith et al., 1986; Srinivas et al., 1994; Urich et al., 1997) . The second, (involving Rac/ MEKK1/MKK4/JNK) is activated by environmental stresses, growth inhibition and programmed cell death; as well as by some mitogens and oncogenes (Crespo et al., 1996; Glenn and Eckhart, 1993; Xu et al., 1996) . The compromised transforming activity of the Y315F mutant middle T was predicted to result from the lack of Ras activation by PtdIns 3-kinase (Hu et al., 1995 , Rodriguez-Viciana et al., 1996 Urich et al., 1995) , and/ or a failure to activate other kinases such as Akt-1 (Franke et al., 1995; Meili et al., 1998) , PKCz (Nakanishi et al., 1993) or p70 s6k (Cheatham et al., 1994; Dahl et al., 1996; Talmage et al., 1988) . Our results do not support this prediction. Instead, the results of experiments using inhibitory drugs or dominant negative mutants indicate that the PtdIns 3-kinase-Rac-JNK module is necessary for ecient cfos promoter transactivation and induction of dense foci by middle T. Retinoic acid, by blocking signaling through this pathway (Figures 3 and 4) , inhibits transformation.
Experiments with cells expressing the Y250S mutant middle T and with the dominant negative RasN17 did not clearly de®ne the putative role of the Ras pathway in middle T transformation. One possible explanation is that middle T signaling via Ras and PtdIns 3-kinase are inter-dependent. Analyses of middle T mutants have demonstrated that both tyrosines 250 and 315 are critical for transformation of cells and for tumor induction. These results implicate both PtdIns 3-kinase and Ras (via Shc binding) involvement in middle T actions (Carmichael et al., 1984; Freund et al., 1992a,b; Talmage et al., 1989; Yi et al., 1997; Bronson et al., 1997; Webster et al., 1998) . Recruitment of Shc to middle T:pp60 c-src signaling complexes is thought to serve two functions; activation of the Ras-MAPK pathway directly and enhancement of accumulation of the PtdIns 3-kinase derived lipid messengers, PtdIns 3,4 bisphosphate and PtdIns 3,4,5 trisphosphate (Ling et al., 1992) . Despite middle T's ability to bind Shc and PtdIns 3-kinase independently, Ras-dependent signaling to MAPK is enhanced by PtdIns 3-kinase binding. This is most clearly shown by the inability of PyY315F middle T, in which Shc binding is largely unaected (Dahl et al., 1996; Yi et al., 1997) to activate MAPK (Urich et al., 1995; Talmage, unpublished observations) . In addition, co-expression of PyY315F and PyY250S middle T mutants does not result in wild type transformation. Co-transfecting F111 cells with both PyY315F and PyY250S expressing plasmids, resulted in only 30% of the number of foci seen with a comparable amount of wild type middle T expressing plasmid (Urich et al., 1995) . Using 10-fold lower amounts of DNA (1 mg/plate rather than 10 mg/plate) we have only seen 1 ± 5% of wild type levels (at our plasmid inputs no foci were seen in cultures transfected with only one of the mutants; data not shown). Thus, signi®cant`cross-talk' between Ras and PtdIns 3-kinase and between Ras and Rac appears to be a key element of middle T signaling. The results presented above ( Figures, 1 and 3d ) demonstrate that PtdIns 3-kinase signaling is largely responsible for middle T eects on c-fos and c-jun expression and AP1 activity.
Our results also establish a novel mechanism for the anti-oncogenic action of retinoic acid. Previously we demonstrated that the active vitamin A metabolite, retinoic acid (RA) inhibited middle T-induced transformation by preventing c-fos expression (Talmage and Lackey, 1992; Talmage and Listerud, 1994) . Because both RA treatment and substitution of phenylalanine for tyrosine at middle T amino acid 315, had similar eects on middle T signaling, we predicted that RA was disrupting one, or more, of the PtdIns 3-kinase signaling pathways. RA does not prevent formation of an active middle T:pp60 c-src : PtdIns 3-kinase complex (Talmage and Lackey, 1992) , but decreases JNK activity in middle T expressing cells and inhibits serum induction of JNK activity in F111-RARa cells (Figure 4) . Similar eects of RA on JNK activity have been reported in F9 embryonal carcinoma cells (Caelles et al., 1997) and human skin (Fisher et al., 1998) .
Treatment of F111-RARa or F111-RARa-PymT cells with RA did not aect middle T or serum induction of the Ras activated MAPK pathway. In preliminary studies, RA failed to inhibit either p70 s6k or Akt activation by middle T (Talmage, unpublished observations) . Since retinoic acid does not block activation of p70 s6k or Akt, and since activation of these kinases by serum growth factors and by middle T is mediated by PtdIns 3-kinase (Cheatham et al., 1994; Chung et al., 1994; Dahl et al., 1996; Franke et al., 1995; Monfar et al., 1995; Talmage et al., 1988; Meili et al., 1998) , we conclude that retinoic acid does not disrupt all signaling events downstream of PtdIns 3-kinase. This conclusion is further supported by the inability of retinoic acid to block middle T activation of MAPK, which is also PtdIns 3-kinase-dependent (Urich et al., 1995; Figure 4) . We propose that a retinoic acid-induced gene product(s) speci®cally inhibits a step in the signaling cascade that leads from PtdIns 3-kinase to JNK. This signaling cascade involves the small GTP-binding protein, Rac and several other protein kinases (Chou and Blenis, 1996; Crespo et al., 1996; Derijard et al., 1995; Franklin and Kraft, 1995; Minden et al., 1994 Minden et al., , 1995 .
Our experiments do not answer the question of how many steps lie between activated JNK and the c-fos promoter. Conceivably, there are as few as one. Middle T transactivation of the c-fos promoter utilizes the SRE and the CRE. Both of these cis-acting elements are potential targets for JNK substrates, either the ternary complex factor Elk-1 (the other known TCF, Sap 1 is not a JNK substrate; Janknecht et al., 1995) or ATF-2 (Gupta et al., 1995) . Our initial eorts at con®rming the role of either Elk-1 or ATF-2 in middle T expressing cells have been inconclusive. Resolution of this question awaits a more detailed analysis of phosphorylation, expression and function of these factors in the cell lines studied here.
Materials and methods

Plasmids
Plasmids expressing the polyoma virus early region were constructed by inserting a BamHI ± EcoRI restriction fragment from the indicated wild type (pPyBR) or mutant viruses into the pUC19 polylinker. This fragment contains non-coding sequences that include the early promoter/enhancer region, the entire coding region for middle and small T antigens, and the N-terminal half of large T (Talmage and Listerud, 1994) . The retroviral vector encoding human RARa cDNA has been described previously (pMV7/RARa; Talmage and Lackey, 1992) . The reporter plasmid containing the mouse c-fos promoter and the bacterial CAT gene has been described (Talmage and Listerud, 1994) . To generate deletion mutations, pF610CAT was digested with HindIII and SmaI, the 5' overhang repaired using a-thio dNTPs, incubated with exonuclease III for 0.5 ± 10 min at 178C, single stranded ends were repaired with S1 nuclease, plasmids recircularized with T4 DNA ligase and transformed into DH5a. Deletions were checked by restriction digestion and endpoints con®rmed by DNA sequencing. pF359CAT contains a 371 base pair PstI fragment of the mouse cfos promoter (+12 through 7359). Point mutations were generated by oligonucleotide-directed mutagenesis using this PstI fragment subcloned into the plasmid, pALTER-1, following the recommended protocol (Promega Biotechnology Inc.). Mutations were con®rmed by DNA sequence analysis of the entire promoter template. Other plasmids were provided by J Blenis (RasN17, Rac1N17 and Cdc42HsN17; Chou and Blenis, 1996) ; A Minden (JNK DN and GST-Jun; Minden et al., 1995) , R Prywse (GST-Elk, pcJunCAT) and G Viglianti (pAP1 5 tkCAT).
Cells
All experiments were done with cell lines derived from the parental F111 rat ®broblast cell line. T antigen expressing lines were generated by calcium phosphate mediated cotransfection of the indicated polyoma early region and pKOneo followed by selection of individual G418 resistant clones (400 mg/ml). Middle T expression, and its interactions with PtdIns 3-kinase and Shc, has been documented in these cell lines (Dahl et al., 1996) . T antigen, RARa coexpressing cells were generated by co-transfection with the indicated polyoma early region and pMV7/RARa followed by isolation of individual drug resistant colonies. T antigen and RARa expression was con®rmed by immunoblot analysis using the F4 anti-T monoclonal (Oncogene Sciences) and a polyclonal rabbit antibody raised against a GST-RARa fusion protein (Talmage, unpublished) . The F111-RARa-1 cell line was described by Talmage and Lackey (1992) .
Growth curves were done by plating 10 4 cells/35 mm tissue culture dish. Twenty-four hours later (T=0) RA was added to the media. Cell numbers were quanti®ed following trypsinization and counting using a standard hemocytometer.
Focus forming assays were performed by co-transfecting F111-RARa cells with wild type pPyBR and the indicated expression vectors, or pPyBR and pCAT-basic (containing the bacterial CAT gene and no promoter sequences to maintain a constant amount of DNA; Promega Biotechnology Inc.). Ratios of pPyBR DNA to the co-transfected plasmid DNAs ranged from 1 : 0.5 to 1 : 5 w/w. When monolayers were 480% con¯uent (2 days post-transfection) serum was reduced to 1.5 ± 2%. Growth media was replenished every 3 days and dense foci were counted after 2 weeks.
Transient expression assays were done as previously described (Talmage and Listerud, 1994) using the indicated target cell lines. Each plate (60 mm) received 2 mg reporter plasmid and 5 mg of indicated second plasmids as a 0.5 ml calcium phosphate precipitate. Total CAT activity was measured in extracts prepared 20 ± 24 h post-transfection. Assays were done using an amount of extract that maintained activity in a linear range (determined to be between 1 and 50% substrate conversion).
Protein kinase assays
Protein kinases (MAPK and JNK) were assayed in immune complex kinase reactions. Cells were washed twice with cold PBS/0.1 mM Na 3 VO 4 , and lysed in 10 mM PIPES, pH 7.0, 10 mM KPO 4 , 1 mM EDTA, 0.5 mM EGTA, 1 mM Na 3 VO 4 , 50 mM b-glycerol phosphate, 0.5% NP40, 0.1% sodium deoxycholate, 0.2 mM PMSF, 5 mM b-mercaptoethanol, 10% glycerol. Lysates were cleared by centrifugation and *200 mg extract protein was immune precipitated with 1 mg antibody for 4 ± 20 h at 48C. Immune complexes were collected with protein A-agarose beads (Repligen, Inc.), washed four times with PBS/1% NP-40 and then once with 10 mM Tris, pH 7.5, 10 mM MgCl 2 . Reactions were carried out on the bead after adding 25 ml reaction buer containing: 20 mM PIPES, pH 7.0, 10 mM MgCl 2 , 1 mg/reaction of PKI and PKC inhibitor peptides (UBI), 5 mM b-mercaptoethanol, 1 ± 2 mCi [g-32 P]ATP and 1 ± 3 mg/reaction of the appropriate substrate. Reactions were stopped after 20 min by adding 75 ml of 1% phosphoric acid (for reactions using peptide substrates) or 5 ml SDS-sample buer (for reactions using protein substrates). Incorporation into peptides was quanti®ed by scintillation counting after spotting the reaction mix on phosphocellulose paper squares which were then washed four times for 15 ± 20 min in 1% phosphoric acid (10 ml/®lter), twice in acetone and dried. Incorporation into protein substrates was analysed by autoradiography following SDS ± PAGE. Antibodies were obtained from either Upstate Biotechnology Inc. (MAPK) or Santa Cruz Biotech (JNK). All peptides were obtained from UBI. Protein substrates used included myelin basic protein (MAPK, Sigma) or GST-Jun (JNK). GST-fusion proteins were prepared by glutathione-sepharose chromatography of E. coli lysates.
Immunoblots
For immunoblotting, cells were lysed by incubating on ice for 1 h, in 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM NaPO 4 , 1% NP-40, 0.1% SDS, 100 mM Na 3 VO 4 , 100 mM NH 4 MoO 3 , 1 mM PMSF. Following clari®cation by centrifugation (10 min at 12 000 g), protein concentrations were measured using Bradford's reagent (BioRad Labs). Lysates (30 mg/lane) were heated in sample buer for 7 min at 958C, resolved by 8% or 10% SDS ± PAGE, and transferred electrophoretically to nitrocellulose membranes. Membranes were blocked with 5% nonfat dry milk in PBS/0.05% Tween-20 and then probed with antirat MAPK R2 (0.25 mg/ml, UBI), anti-Cdc42Hs (0.5 mg/ ml, Santa Cruz), anti-Rac1 (0.5 mg/ml, UBI.) or anti-JNK (0.5 mg/ml, Santa Cruz). Bands were visualized by enhanced chemiluminescence (ECL, Amersham).
